KLK3 and pachyonychia congenita: Historically, bicalutamide has been commonly used in the treatment of various stages of PC due to its global accessibility, relatively low cost, once-daily dosing formulation, well-established safety profile, and ability to reduce PSA levels [5, 32, 33].